Jason Ramirez

Personal Statement

I came to the University of Washington in 2014 as a postdoctoral fellow supported by the National Institute on Alcohol Abuse and Alcoholism and has been faculty here since 2016. My research interests include examination of cognitive and psychosocial processes thought to underlie substance misuse predominantly among adolescents and young adults. Support for my work has been provided by the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and by the Alcohol and Drug Abuse Institute at the University of Washington.

Mark Sullivan

Personal Statement

My clinical service and research focuses on the interaction of mental and physical illness, especially in patients with chronic pain. Much of my research in recent decades has focused on the risks of treating chronic pain with opioids. I have developed educational programs and outcome tracking tools to assist with opioid treatment of chronic pain. I have published a book about patient empowerment in chronic disease care, The Patient as Agent of Health and Health Care (Oxford, 2017). I have another book written with Jane Ballantyne forthcoming, The Right to Pain Relief and other deep roots of the opioid epidemic (Oxford, 2022).

Sarah Cusworth Walker

Personal Statement

I am interested in methods of evidence translation and knowledge exchange that improve system and policymaking in behavioral health with a focal interest in public mental health for children and juvenile justice system reform.

Peter Vitaliano

Personal Statement

Over the last 25 years, my work has focused on relationships between stress and health in several risk groups (spouse caregivers of persons with Alzheimer’s disease, medical students, psychiatric/medical outpatients/inpatients, air traffic controllers, and camp counselors). We have developed and/or revised measures of medical student stress, caregiver burden, patient anger/dyscontrol, process coping, appraisal, neuropsychological function and physician awareness of patient problems. These measures have been used by university researchers, insurance companies, pharmaceutical companies in clinical trials, prisons, nursing homes/long term care, rehabilitation facilities, and public health organizations. These psychosocial and behavioral measures have been shown to predict and be predicted by physiological and cognitive measures. We have also focused on moderators of such relationships, such as gender, personality, and co-morbidities. We have used primarily multicohort long-term studies that allow for interactions between exposures to stressors, hard-wired vulnerabilities, and more temporal resources. We attempted to identify mechanisms that can be potentially altered to have long-term public health significance in persons under chronic stress. I have also attempted to isolate groups that are at high risk for negative outcomes. In a perfect world, interventions should be used to help all persons who have deleterious responses to stress, but society cannot afford this. For this reason, the identification of high risk groups is imperative for maximizing the effect of interventions.

My research program’s long range goal is to better understand the mechanisms by which chronic stress translates into physical, mental, or cognitive health problems. We are examining caregivers of spouses with AD and demographically-similar spouse non-caregivers across time and assessing the degree to which elevated depression, stress hormones, inflammation, and insulin resistance in caregivers predict cognitive decline in caregivers relative to non-caregivers. We are also attempting to replicate our earlier work that showed that chronic stress and chronic disease moderate each other’s physiological risks. For example, physiological dysregulation that is specific to a disease (e.g., metabolic syndrome with CHD, blood pressure reactivity with hypertension, and immune function with cancer history, HbA1c with diabetes) is exacerbated in caregivers with a chronic disease relative to non-caregivers with a chronic disease, but no such differences occur in caregivers versus non-caregivers without a chronic disease. Finally, we are examining a large cohort of older adults sampled from various U.S. communities in order to assess the influence of life stressors on long term cognitive function and potential mediators of such changes.

Katherine Anne (Kate) Comtois

Personal Statement

My career goal is to give suicidal clients and their clinicians the best chance to succeed. I have been working in the area of health services, treatment development, and clinical trials research to prevent suicide for over 30 years. My graduate training was in community/clinical psychology and focused on achieving clinical ends through prevention and other systemic interventions in socio-culturally diverse populations. I have brought these perspectives into health services research.  I have developed or adapted interventions to improve care and clinician willingness to work with suicidal patients including Caring Contacts, Dialectical Behavior Therapy (DBT), Collaborative Assessment and Management of Suicidality (CAMS), and Preventing Addiction Related Suicide (PARS). I have developed an adaptation of DBT Next Steps, a program to assist psychiatrically disabled individuals find and maintain living wage employment. My research has been funded by NIMH, NIDA, the Department of Defense, American Foundation for Suicide Prevention, and the State of Washington.

I am the director of the Center for Suicide Prevention and Recovery (CSPAR) whose mission is to promote the recovery of suicidal individuals and the effectiveness and well-being the clinicians and families who care for them by conducting rigorous and ecologically valid research, developing innovative interventions, improving policies, systems and environments of care, and providing expert training and consultation. CSPAR faculty and staff seek a deep understanding of the cultures and settings in which we work that leads to meaningful and effective interventions ready for implementation.

I also direct the Suicide Care Research Center, an NIMH P50 funded research center focused on using Human Centered Design and MOST optimization methodology to improve the care of adolescents and young adults (age 13-30 years) in outpatient medical settings. We are conducting one fully powered trial, three R34s, and 4 pilot studies within UW Medicine and Seattle Children’s hospital to develop innovative interventions to support primary care, Collaborative Care, and specialty medical clinics care for patients experiencing suicidal thoughts and behavior. The center supports effort of over 20 faculty and 16 staff as well as 11 emerging and advanced collaborating scholars and funds 2 annual pilot grants (each $100,000 over two years).

In addition to clinical research, I founded the Society for Implementation Research Collaboration (SIRC) focused on disseminating and implementing innovative, evidence-based interventions in the systems that need them. Beyond my research, I directed the Harborview Dialectical Behavior Therapy program at Harborview Medical Center 1996-2019, co-lead the UWAnnual Comprehensive DBT Training Program and Suicide Care in Healthcare Systems: We Can Do Better Serving our Patients and Caring for our Clinicians, both of which meet the Washington State requirement for suicide prevention training.  I have a long history of training and mentoring junior faculty, post-doctoral scholars, psychiatry residents, pre-doctoral psychology interns, undergraduate students, and post-baccalaureate trainees. I provide psychotherapy and consultation at the UWMC Outpatient Psychiatry Clinic.

Laurel Pellegrino

Personal Statement

I am a psychiatrist at the UW Outpatient Psychiatry Clinic (OPC) on Roosevelt, where I see patients for consultation, medication management, and psychotherapy, both individually and with psychiatry residents. I see patients with mood disorders, anxiety disorders, trauma, and complex trauma. I also help answer a consultation line for providers in the state of Washington who have questions about psychiatric medications during the perinatal period. I serve as an Associate Program Director in the Psychiatry residency, where I help oversee the curriculum. My areas of interests are resident education, psychodynamic psychotherapy, outpatient psychiatry, perinatal psychiatry, and diversity, equity, and inclusion.

Mark Reger

Personal Statement

I am the ​Senior Manager for Mental Health at the Office of Research & Development in the Veterans Health Administration and Professor of Psychiatry & Behavioral Sciences at the University of Washington School of Medicine. I am a suicide prevention researcher and health services investigator who has served as the principal investigator for a variety of large federally-funded suicide prevention studies. My research focuses on Veteran and military suicide prevention. I am interested in risk and protective factors that are unique to the military community. My work focuses on systematic clinical and public health approaches to reducing suicide behaviors. I have had the opportunity to contribute to national initiatives to translate research into policy and best-practices, and I have been fortunate to have my work highlighted in interviews with numerous national TV, radio, and news outlets.

Mark Stein

Personal Statement

I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to  our behavioral group treatment programs and treatment recommendations.   The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves  diagnostic evaluations and consultations  for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for  individuals with ADHD.    I have  assisted in the development of several stimulant  and non stimulant medications, and participated in many clinical trials. Currently, we are   conducting a study  for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication  and  behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD,  and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.

Heather Carmichael Olson

Personal Statement

I am a psychologist who carries out research, provides community education to a broad range of audiences, trains postgraduate students, works on public policy– and has served as a clinician with children and families for many years. My main interests are fetal alcohol spectrum disorders (FASD), early childhood mental health, and interventions for children born prenatally exposed to alcohol and other drugs and their families. My research is currently based at the Seattle Children’s Research Institute, but I also work in collaboration with UW researchers– and scientists at the University of Rochester in New York and multiple other academic institutions. A main research focus has been the Families Moving Forward (FMF) Program, a family-focused FASD intervention, now being disseminated primarily in the USA and Canada.  The FMF Program is also now being translated into a mobile health application, called FMF Connect, for even broader use. Through Seattle Children’s, I co-direct a pilot service focused on assessment and short-term consultation for youth with prenatal substance exposure (including alcohol), and their families. I also offer mental health services to a broad range of young children and develops research focused on early childhood mental health. Over the years, beyond research and clinical work, I have been able to work toward change in national US public policy, collaborate with Indigenous communities and researchers in remote Northwestern Australia, and train dedicated young professionals in psychology and psychiatry. I am grateful for these remarkable career opportunities… and the chance to meet so many resilient and inspiring families. Note that you can only reach me through my Seattle Children’s email, at: heather.carmichaelolson@seattlechildrens.org

Erik S. Carlson

Personal Statement

I am a basic neuroscientist, a board-certified practicing psychiatrist, and an Assistant Professor of Psychiatry and Behavioral Sciences at the University of Washington Medical School. The goal of my research is to investigate the neural circuitry of cognitive, emotional and memory processing, particularly as it relates to the cerebellum, and illnesses affecting cerebellum including cognitive disorders, PTSD, TBI and dementia through the implementation of techniques in mouse behavioral genetics. In my clinical practice, I primarily see veterans with PTSD, mild cognitive impairment, and various forms of dementia in an outpatient clinic at the VAMC Puget Sound Geriatric Research, Education, and Clinical Center (GRECC) in Seattle. I have over 15 years of experience in basic science research with most of that time dedicated to the use of mouse models of neuropsychiatric disorders.   Throughout my training prior to and during graduate school, I gained background in many contemporary molecular and biochemical lab techniques, such as molecular cloning, protein biochemistry, protein crystal production, fluorometric measurement of protein kinetics, in vivo NMR spectroscopy, gene targeting, microarray genomics, immunohistochemistry, and mammalian cell culture. I have a foundation in mouse genetics, neural development, and behavior which I developed in Michael Georgieff’s lab by investigating the role of iron in developing pyramidal neurons of the mouse hippocampus. During graduate training, I also received cross-training in child psychological development. In graduate school, I developed two mouse models of nonanemic neuron specific iron deficiency: 1) a conditional knockout of the Slc11a2 gene, encoding the iron transporter DMT-1 in forebrain neurons, including hippocampal pyramidal neurons, and 2) a transgenic mouse with a reversibly inducible dominant negative (nonfunctional) form of the transferrin receptor expressed only in hippocampal pyramidal neurons. I utilized and implemented different versions of the Morris Water Maze to study learning deficits in these mouse models of perinatal brain iron deficiency, a condition that is often a consequence of diabetes during pregnancy.   During my residency training, I expanded my knowledge of neuropsychiatric disorders by directly evaluating and treating patients with neuropsychiatric disorders including PTSD, schizophrenia, Alzheimer’s disease, autism, major depression, substance abuse disorders, and personality disorders. I learned numerous pharmacological, neuromodulatory, and psychotherapeutic interventions and participated in the internally funded Neuroscience Research Track. I then received a NIMH career development award (K08) mentored by Larry Zweifel, Ph.D. In that position, I investigated interactions between catecholamines and the cerebellum in decision making, emotional and cognitive processing. In the 5 years I was in Dr. Zweifel’s lab, I learned many additional new techniques including use of viral vectors, in vivo electrophysiology, and several operant- and threat-based behaviors, and moved forward in my goal of becoming a physician scientist isolating important circuits underlying etiology of specific domains of behavioral function. This work culminated in my receiving an RO1 independent investigator award, without any gap in funding.   My current research utilizes mouse behavior, in vivo electrophysiological recordings, gene targeting, viral vectors, translational profiling, chemo- and optogenetic tools, site-specific intracranial viral vector injection, and protein chemistry. I am now forging my path as an independent investigator, and my primary goal is to understand cerebellar circuits as they relate to psychiatric and neurodegenerative illnesses and utilize this knowledge to inform and improve current and novel psychiatric illnesses, primarily in cognitive and emotional domains. As such, I am pursuing a multidisciplinary approach combining genetic, electrophysiological, pharmacological, and behavioral techniques.